Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Graphene Quantum Dot Sensitized Heterojunctions Induce Tumor-Specific Cuproptosis to Boost Sonodynamic and Chemodynamic Enhanced Cancer Immunotherapy.

doi: 10.1002/advs.202410606

Figure Lengend Snippet: Figure 6. a) CRT levels in 4T1 cells were measured following various treatments. b) Following different treatments, Western blot analysis was used to examine the presence of DLAT and DLAT oligomers in 4T1 cells. c,d) By utilizing flow cytometry, we determined the expression of CD80 and CD86 in DCs. e) WB analysis of FDX1 and LIAS in 4T1 cells after different treatments. f) Bio-TEM images of 4T1 cells before and after GQD/Cu2O + US treatment. Statistical significance between the experimental group and the control group is calculated with a two-tailed Student’s t-test. Data are presented as the mean ± SD. (n = 3). *p < 0.05 and ***p < 0.001.

Article Snippet: After incubation with antibodies to DLAT (1:20 000, proteintech), LIAS (1:1000, Abcam), FDX1 (1:1000, Abcam), γ-H2AX (Abcam), or α- tubulin (1:1000, Abcam), the cell lysates were analyzed and detected with a chemiluminescent imaging system.

Techniques: Western Blot, Cytometry, Expressing, Control, Two Tailed Test

Journal: Biomolecules

Article Title: Copper Chelation by Penicillamine Protects Against Doxorubicin-Induced Cardiomyopathy by Suppressing FDX1-Mediated Cuproptosis

doi: 10.3390/biom15091320

Figure Lengend Snippet: Two-dimensional and 3D interaction diagrams represent the key for the types of interaction between controls and selected protein receptors: ( A ) FDX1 (ferredoxin 1) 3P1M protein, ( C ) SLC31A13 2LS2 protein, ( E ) DLAT (dihydrolipoamide acetyltransferase) 3B8K protein. penicillamine and selected protein receptors: ( B ) FDX1 (ferredoxin 1) 3P1M protein, ( D ) SLC31A13 2LS2 protein, ( F ) DLAT (dihydrolipoamide acetyltransferase) 3B8K protein.

Article Snippet: 3-μm-thickness paraffin sections were prepared and used for HE staining (for examination of the morphological changes); MT staining (for analysis of collagen and extracellular matrix “ECM” deposition); and immunohistochemical staining for the cuproptosis dynamic protein markers (SLC31A1, FDX1, and DLAT), using anti-SLC31A1/CTR1 antibody (Cat. No. GTX48534, GeneTex, Irvine, CA, USA); Anti FDX1 Polyclonal antibody (Cat. No. 12592-1-AP, Proteintech, Chicago, IL, USA); and anti-DLAT antibody (Cat. No. CSB- PA445587 , CUSABIO, Houston, TX, USA), respectively ( ).

Techniques:

Journal: Science Advances

Article Title: Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut

doi: 10.1126/sciadv.aeb5934

Figure Lengend Snippet: ( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and DLD1 (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.

Article Snippet: For fluorescent imaging, the cells were gently washed with Dulbecco’s phosphate-buffered saline (DPBS; WELGENE) and subsequently stained with SDHB antibody (Abcam, ab14714), fluorescein isothiocyanate (FITC)–conjugated LIAS antibody (SUNLONG, SL18247R-FITC), FITC-conjugated DLAT antibody (biorbyt, orb400442), and Alexa Fluor 647–conjugated adrenal ferredoxin (FDX1) antibody (Mybiosource, MBS9453137).

Techniques: In Vitro, Immunofluorescence, Imaging, Biomarker Discovery, Live Dead Assay, ATP Assay, Comparison

Journal: Materials Today Bio

Article Title: Cu-doped dendritic biodegradable nanoplatforms for augmenting cuproptosis and tumor-starvation therapy through mitochondrial metabolic cascade modulation

doi: 10.1016/j.mtbio.2025.102477

Figure Lengend Snippet: In vivo antitumor effects of XQ/Gp@CMSNs (I: PBS, II: Gp, III: PEG/CMSNs, IV: PEG/Gp@CMSNs, V: XQ/CMSNs, VI: XQ/Gp@CMSNs). (a) Schematic illustration of PATU-8988 tumor xenograft establishment and treatment. (b) In vivo fluorescence imaging of PATU-8988 tumor-bearing mice after intravenous injection of Cy5.5-loaded PEG/CMSNs and XQ/CMSNs. The red circles indicate the tumor sites. (c) Ex vivo fluorescence images of tumor tissues and major organs collected from mice at 36 h postinjection of Cy5.5-loaded PEG/CMSN and XQ/CMSNs. (d, e) Tumor volume curves after the mice (n = 5) received different treatments. (e) Tumor volume and (f) tumor weight on the 14th day after different treatments (n = 5). (g) Pictures of tumors dissected on the 14th day after different treatments. (h) FDX1, DLAT, and BCAT1 staining of sliced tumors from different groups; scale bars = 100 μm. Intergroup comparison was performed using the t -test. a Not significant, b p < 0.05, and c p < 0.0001 (compared with the group I). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: All other antibodies (dihydrolipoamide S-acetyltransferase (DLAT), ferredoxin-1 (FDX1), lipoyl synthase (LIAS) and branched chain aminotransferase 1 (BCAT1)) were purchased from Sanying Biology Technology Co. (Wuhan, China).

Techniques: In Vivo, Fluorescence, Imaging, Injection, Ex Vivo, Staining, Comparison